Reduce the risk of hospitalization or death by 90% Pfizer announces latest data on oral anti-corona therapy

Oral anti-coronavirus therapy can allow patients to take it directly at home when they first develop symptoms or find that they are infected with the new crown virus, which may reduce the risk of aggravation of the disease, leading to hospitalization or death of the patient

Today, Pfizer announced the latest clinical trial results of its oral anti-coronavirus treatment Paxlovid

The final analysis of clinical trials conducted in patients with high risk of developing severe COVID-19 showed that 0.

Among the patients who received treatment within 5 days after the onset of symptoms, 0.

External experts said that the effect of receiving treatment within 3 days of the onset of symptoms is similar to that of receiving treatment within 5 days, which means that patients who are diagnosed have more opportunities to receive medication

In this clinical trial, researchers tested the new coronavirus load of 499 patients at baseline and 5 days after receiving treatment

In another phase 2/3 clinical trial, adult COVID-19 patients who have not been vaccinated with the new crown vaccine but have not developed severe risk factors (including those who are older than 65 years old, obese, or have underlying diseases, etc.

This clinical trial also analyzed whether Paxlovid treatment can continue to relieve the symptoms of COVID-19 for 4 consecutive days.

Paxlovid is composed of the new coronavirus 3CL protease inhibitor nirmatrelvir (PF-07321332) and the antiviral therapy ritonavir (ritonavir)

At present, a variety of new coronaviruses that have received attention may be resistant to preventive or therapeutic methods against the spike protein on the surface of the virus, and the target of nirmatrelvir is the protease in the virus

Reference materials:

[1] Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death.

[2] Pfizer's Covid pill remains 89% effective in final analysis, company says.

(The original text has been deleted)